These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34589505)

  • 1. IL-33 in Rheumatic Diseases.
    Dong Y; Zhong J; Dong L
    Front Med (Lausanne); 2021; 8():739489. PubMed ID: 34589505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases.
    Rostan O; Arshad MI; Piquet-Pellorce C; Robert-Gangneux F; Gangneux JP; Samson M
    Infect Immun; 2015 May; 83(5):1738-48. PubMed ID: 25712928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family.
    Cayrol C; Girard JP
    Immunol Rev; 2018 Jan; 281(1):154-168. PubMed ID: 29247993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation.
    Takatori H; Makita S; Ito T; Matsuki A; Nakajima H
    Front Immunol; 2018; 9():2004. PubMed ID: 30233590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases.
    Chen WY; Tsai TH; Yang JL; Li LC
    Cell Physiol Biochem; 2018; 49(1):349-358. PubMed ID: 30138941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-33/ST2 Axis in Organ Fibrosis.
    Kotsiou OS; Gourgoulianis KI; Zarogiannis SG
    Front Immunol; 2018; 9():2432. PubMed ID: 30405626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.
    Griesenauer B; Paczesny S
    Front Immunol; 2017; 8():475. PubMed ID: 28484466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells.
    Hayakawa H; Hayakawa M; Tominaga SI
    Biochem Biophys Rep; 2016 Mar; 5():401-407. PubMed ID: 28955848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-9 and T helper type 9 cells in rheumatic diseases.
    Ciccia F; Guggino G; Ferrante A; Cipriani P; Giacomelli R; Triolo G
    Clin Exp Immunol; 2016 Aug; 185(2):125-32. PubMed ID: 27159882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis.
    Chen WY; Wu YH; Tsai TH; Li RF; Lai AC; Li LC; Yang JL; Chang YJ
    Theranostics; 2021; 11(6):2594-2611. PubMed ID: 33456562
    [No Abstract]   [Full Text] [Related]  

  • 11. IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFβ Release.
    Siede J; Fröhlich A; Datsi A; Hegazy AN; Varga DV; Holecska V; Saito H; Nakae S; Löhning M
    PLoS One; 2016; 11(8):e0161507. PubMed ID: 27548066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review.
    Tonacci A; Quattrocchi P; Gangemi S
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30769901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases.
    Sherlock JP; Taylor PC; Buckley CD
    Curr Opin Rheumatol; 2015 Jan; 27(1):71-5. PubMed ID: 25415528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.
    Matta BM; Reichenbach DK; Zhang X; Mathews L; Koehn BH; Dwyer GK; Lott JM; Uhl FM; Pfeifer D; Feser CJ; Smith MJ; Liu Q; Zeiser R; Blazar BR; Turnquist HR
    Blood; 2016 Jul; 128(3):427-39. PubMed ID: 27222477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Natural Killer Cells in Autoimmune Diseases.
    Kucuksezer UC; Aktas Cetin E; Esen F; Tahrali I; Akdeniz N; Gelmez MY; Deniz G
    Front Immunol; 2021; 12():622306. PubMed ID: 33717125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
    Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
    Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.
    Choi MR; Sosman JA; Zhang B
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic Effects of IL-33 on CD4
    Alvarez F; Fritz JH; Piccirillo CA
    Front Immunol; 2019; 10():522. PubMed ID: 30949175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Roles of IL-33/ST2 Axis in Renal Diseases.
    Chen WY; Li LC; Yang JL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28387719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of interaction between IL-33 and ST2+ regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration.
    Noel G; Arshad MI; Filliol A; Genet V; Rauch M; Lucas-Clerc C; Lehuen A; Girard JP; Piquet-Pellorce C; Samson M
    Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G313-23. PubMed ID: 27340126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.